Enhancing spleen function for effective hyperuricemia treatment

doi:10.5246/jcps.2025.02.008

Abstract

Abstract:

Hyperuricemia (HUA) is a metabolic disorder characterized by elevated levels of uric acid in the blood, resulting from either increased production or decreased excretion of uric acid. This condition has reached epidemic proportions. Conventional Western medical treatments often come with a range of adverse effects. According to traditional Chinese medicine (TCM), the root cause of HUA lies in the spleen’s insufficient healthy movement, with phlegm, dampness, turbidity, and stasis being symptomatic manifestations. Research has shown that spleen-strengthening herbal remedies can effectively treat HUA by inhibiting uric acid synthesis enzymes, promoting uric acid excretion, reducing inflammation, providing antioxidant benefits, regulating gut microbiota, and modulating cellular processes. Clinical applications have substantiated these findings. Therefore, from the standpoint of symptomatic treatment of HUA, spleen-strengthening therapies hold significant importance and potential.

Key words: Strengthening the spleen, Hyperuricemia, Diagnosis, Treatment

Supporting:

Qian Deng, Zining Peng, Fanyu Meng, Weitian Yan, Nian Liu, Jiangyun Peng. Enhancing spleen function for effective hyperuricemia treatment[J]. Journal of Chinese Pharmaceutical Sciences, 2025, 34(2): 99-108.

References 50

[1]	Wei, X.; Zhang, M.; Huang, S.A.; Lan, X.Z.; Zheng, J.; Luo, H.; He, Y.; Lei, W. Hyperuricemia: a key contributor to endothelial dysfunction in cardiovascular diseases. FASEB J. 2023, 37, e23012.
[2]	Chinese Society of Endocrinology. Chinese Medical Association. Chinese guidelines for the diagnosis and treatment of hyperuricemia and gout (2019). Chin. J. Endo. Meta. 2020, 36, 1–13.
[3]	Wei, Y.D.; Zhu, J.M.; Wetzstein, S.A. Plasma and water fluoride levels and hyperuricemia among adolescents: a cross-sectional study of a nationally representative sample of the United States for 2013–2016. Ecotoxicol. Environ. Saf. 2021, 208, 111670.
[4]	Kumar, J.; Gupta, A.; Dev, K.; Kumar, S.; Kataria, D.; Gul, A.; Abbas, M.; Jamil, A.; Shahid, S.; Memon, S. Prevalence and causes of hyperuricemia in children. Cureus. 2021, 13, e15307.
[5]	Li, Y.; Shen, Z.Y.; Zhu, B.W.; Zhang, H.; Zhang, X.Y.; Ding, X.Q. Demographic, regional and temporal trends of hyperuricemia epidemics in mainland China from 2000 to 2019: a systematic review and meta-analysis. Glob. Health Action. 2021, 14, 1874652.
[6]	Stamp, L.K.; Day, R.O.; Yun, J. Allopurinol hypersensitivity: investigating the cause and minimizing the risk. Nat. Rev. Rheumatol. 2016, 12, 235–242.
[7]	Pei, Y.; Wang, R.; Wang, D.D.; Guo L.; Wang B.; Kang H.Y. Literature analysis of HLA-B5801 polymorphisms and cutaneous adverse reactions induced by allopurinol. Chin. J. Pharm.* 2019, 3, 154–156, 163.
[8]	Paul, B.J.; Anoopkumar, K.; Krishnan, V. Asymptomatic hyperuricemia: is it time to intervene? Clin. Rheumatol. 2017, 36, 2637–2644.
[9]	Gong, F.; Wen, X.L.; Jie, Z.; Qing, H.K.; Xing, H.Z.; Li, H.L.; Chang, H.L. Safety and tolerability of available drugs for hyperuricemia: a critical. J. Chin. Pharm. Sci. 2022, 31, 397–411.
[10]	Xiao, W.C.; Qi, L.; Yi, Z.; Tong, G.; Chu, X.Y.; Liang, R.Z.; Zhen M.L. Discovery of potential xanthine oxidase inhibitors based on virtual screening. J. Chin. Pharm. Sci. 2023, 32, 626–635.
[11]	Arakawa, H.; Amezawa, N.; Katsuyama, T.; Nakanishi, T.; Tamai, I. Uric acid analogue as a possible xenobiotic marker of uric acid transporter Urat1 in rats. Drug Met. Pharm. 2019, 34, 155–158.
[12]	Dalbeth, N.; Gosling, A.L.; Gaffo, A.; Abhishek, A. Gout. Lancet. 2021, 397, 1843–1855.
[13]	Gong, F.; Wen, X.L. Advances in the treatment of hyperuricemia with traditional Chinese medicin. J. Chin. Pharm. Sci. 2024, 33, 381–395.
[14]	Wang, Y.; Lin, Z.J.; Zhang, B.; Jiang, Z.X.; Guo, F.F.; Yang, T. Cichorium intybus L. extract suppresses experimental gout by inhibiting the NF-κB and NLRP3 signaling pathways. Int. J. Mol. Sci. 2019, 20, 4921.
[15]	Liu, S.M.; Zhang, N.; Yu, D.H.; Wang, Y.; Zhou, Q.; Lu, F. Liver metabonomics of acute gouty arthritis treated by Diosocorea nipponica. Chin. J. Mater. Med. 2017, 42, 1971–1978.
[16]	Sun, K.X. Screening and activity of food homologous materials for urate-lowering drugs. Shandong Agri. Univ. 2023.
[17]	Li, J.; Jiang, L.L.; Li, M.X.; Deng F.; Xu, S.Y.; Xue, X.; Hu R.P.; Xue, H.T. Inhibitory effects of astragalus polysaccharide on activity of xanthine oxidase. Food Sci. Bio. 2021, 40, 16–20.
[18]	Zhao, Z.T.; Nian, S.H.; Sun, X.Q.; Wang, W.; Zhang, Q.; Peng, D.Y.; Zhou, L.Y. Study on the effect of lowering uric acid and effect on the kidney of Poriae cutis in hyperuricemiamice. J. Hainan Med. Univ. 2023, 29, 168–174.
[19]	Zhang, R.; Zhan, S.Y.; Li, S.Y.; Zhu, Z.Z.; He, J.R.; Lorenzo, J.M.; Barba, F.J. Anti-hyperuricemic and nephroprotective effects of extracts from Chaenomeles sinensis (Thouin) Koehne in hyperuricemic mice. Food Funct. 2018, 9, 5778–5790.
[20]	Liu, T. Study on the effect of MuGua Huazhuo decoction on hyperuricemia mice and its mechanism. Guangdong Pharm. Univ. 2021.
[21]	Naboka, O.; Vyshnevska, L.; Pasynchuk, I.; Filiptsova, O.; Tkachenko, O.; Vislous, O. Pharmacological study of original extracts of corn silk. ScienceRise Biol. Sci. 2022, 4, 10–17.
[22]	Huang, Y.H.; Xu, S.; Fang, W.; Song, W.; He, Y.J.; Zhang, Y.X.; Ma, Z.Y. Anti-hyperuricemia and renal protection effects of total flavonoids from corn silk. J. Zhengzhou Univ. (Med. Sci.). 2024, 59, 45–50.
[23]	Li, D.L.; Yuan, S.Y.; Deng, Y.Y.; Wang, X.W.; Wu, S.H.; Chen, X.S.; Li, Y.M.; Ouyang, J.T.; Lin, D.Y.; Quan, H.H.; Fu, X.W.; Li, C.; Mao, W. The dysregulation of immune cells induced by uric acid: mechanisms of inflammation associated with hyperuricemia and its complications. Front. Immunol. 2023, 14, 1282890.
[24]	Yang, L.T.; Wang, B.; Ma, L.; Fu, P. Traditional Chinese herbs and natural products in hyperuricemia-induced chronic kidney disease. Front. Pharmacol. 2022, 13, 971032.
[25]	Bian, M.; Wang, J.; Wang, Y.; Nie, A.Z.; Zhu, C.S.; Sun, Z.X.; Zhou, Z.; Zhang, B. Chicory ameliorates hyperuricemia via modulating gut microbiota and alleviating LPS/TLR4 axis in quail. Bio. Pharm. 2020, 131, 110719.
[26]	Yang, Y.; Zhang, D.M.; Liu, J.H.; Hu, L.S.; Xue, Q.C.; Ding, X.Q.; Kong, L.D. Wuling San protects kidney dysfunction by inhibiting renal TLR4/MyD88 signaling and NLRP3 inflammasome activation in high fructose-induced hyperuricemic mice. J. Ethnopharmacol. 2015, 169, 49–59.
[27]	Chen, X.; Ge, H.Z.; Lei, S.S.; Jiang, Z.T.; Su, J.; He, X.; Zheng, X.; Wang, H.Y.; Yu, Q.X.; Li, B.; Lv, G.Y.; Chen, S.H. Dendrobium officinalis six nostrum ameliorates urate under-excretion and protects renal dysfunction in lipid emulsion-induced hyperuricemic rats. Bio. Pharm. 2020, 132, 110765.
[28]	Ge, H.Z.; Jiang, Z.T.; Li, B.; Xu, P.Y.; Wu, H.S.; He, X.; Xu, W.F.; Huang, Z.; Xiong, T.X.; Wang, P.; Lv, G.Y.; Chen, S.H. Dendrobium officinalis six nostrum promotes intestinal urate underexcretion via regulations of urate transporter proteins in hyperuricemic rats. Comb. Chem. High Throughput Screen. 2023, 26, 848–861.
[29]	Wei, W.J.; Gao, X.; Lei, Y.; Yang, X.B.; Hui, Y.Y. Protective effect of oxymatrine on myocardial injury in septic shock rats through TGF-β1/Smads signaling pathway. Pro. Modern Bio. 2023, 23, 1436–1441.
[30]	Yin, N.; Li, X.S.; Liu, W.C.; Qi, Y.; Wu, R.F.; Li, Z.F.; Ying, S.; Yang, H.H.; Gu, Q.L.; Wu, Z.; Zou, N.T.; Duan, W.G.; Peng, J.Y.; Wan, C.P. Jian Pi Shen Shi formula alleviates hyperuricemia and related renal fibrosis in uricase-deficient rats via suppression of the collagen-binding pathway. Int. J. Rheum. Dis. 2022, 25, 1395–1407.
[31]	Lu, M.X.; Yin, J.Y.; Xu, T.S.; Dai, X.; Liu, T.Y.; Zhang, Y.Y.; Wang, S.; Liu, Y.G.; Shi, H.F.; Zhang, Y.F.; Mo, F.F.; Sukhorukov, V.; Orekhov, A.N.; Gao, S.H.; Wang, L.L.; Zhang, D.W. Fuling-Zexie formula attenuates hyperuricemia-induced nephropathy and inhibits JAK2/STAT3 signaling and NLRP3 inflammasome activation in mice. J. Ethnopharmacol. 2024, 319, 117262.
[32]	Liu, N.; Xu, H.; Sun, Q.Q.; Yu, X.J.; Chen, W.T.; Wei, H.Q.; Jiang, J.; Xu, Y.Z.; Lu, W.J. The role of oxidative stress in hyperuricemia and xanthine oxidoreductase (XOR) inhibitors. Oxid. Med. Cell Longev. 2021, 2021, 1470380.
[33]	Chen, T.R.; Pubu, D.J.; Zhang, W.H.; Meng, S.Y.; Yu, C.C.; Yin, X.Q.; Liu, J.L.; Zhang, Y.H. Optimization of the extraction process and metabonomics analysis of uric acid-reducing active substances from Gymnadenia R.Br. and its protective effect on hyperuricemia zebrafish. Front. Nutr. 2022, 9, 1054294.
[34]	Wang, Y.X.; Wu, Y.S.; Zhang, C.Y.; Gao, J.D. Effects of compound recipe of reducing uric acid on oxidative stress and renal inflammatory state inrats with hyperuricemia. Acade. J. Shanghai Univ. TCM. 2018, 32, 80–85
[35]	Jiang, X.C.; Tian, D.Z.; Liu, Q.; Jiang, X.Y.; Yu, H.; Yu, W.Y.; Xiao, M.; Cao, J.G. Shenling Baizhusan improves spermatogenesis in hyperuricemia oligoasthenospermia mice by regulating Nrf2/ARE pathway. Chin. J. Exper. Trad. Med. Form. 2023, 29, 22–30.
[36]	Khoury, T.; Tzukert, K.; Abel, R.; Abu Rmeileh, A.; Levi, R.; Ilan, Y. The gut-kidney axis in chronic renal failure: a new potential target for therapy. Hemodial. Int. 2017, 21, 323–334.
[37]	Meng, D.L.; Liang, L.X.; Song, H.Y. Physiological function of short-chain fatty acids in the intestine. Chin. J. New Clin. Med. 2018, 11, 198–202.
[38]	García-Arroyo, F.E.; Gonzaga, G.; Muñoz-Jiménez, I.; Blas-Marron, M.G.; Silverio, O.; Tapia, E.; Soto, V.; Ranganathan, N.; Ranganathan, P.; Vyas, U.; Irvin, A.; Ir, D.; Robertson, C.E.; Frank, D.N.; Johnson, R.J.; Sánchez-Lozada, L.G. Probiotic supplements prevented oxonic acid-induced hyperuricemia and renal damage. PLoS One. 2018, 13, e0202901.
[39]	Wang, F.; Xin, K.; Chen, L.; Li, S.S.; Li, J.F. Regulatory effect of Dizhuo decoction on intestinal dysbiosis in hyperuricemic rats based on TLR4/NF-κB signaling pathway. Chin. J. Microecol. 2024, 36, 10–17, 28.
[40]	Jia, E.T.; Jiang, Y.K.; He, S.H.; Zhang, J.Y. Effect of Ci Ling Huazhuo Granules on Gut Microbiome in Gout Patients. J. Guangzhou Univ. TCM. 2022, 39, 522–526.
[41]	Zhong, C.S.; Zeng, B.; Qiu, J.H.; Xu, L.H.; Zhong, M.Y.; Huang, Y.T.; Xu, R.; Liu, S.Y.; Zha, Q.B.; Hu, B.; Ou-Yang, D.Y.; He, X.H. Gout-associated monosodium urate crystal-induced necrosis is independent of NLRP3 activity but can be suppressed by combined inhibitors for multiple signaling pathways. Acta Pharmacol. Sin. 2022, 43, 1324–1336.
[42]	Yu, W.; Liu, W.D.; Xie, D.; Wang, Q.; Xu, C.X.; Zhao, H.R.; Lv, J.M.; He, F.R.; Chen, B.Y.; Yamamoto, T.; Koyama, H.; Cheng, J.D. High level of uric acid promotes atherosclerosis by targeting NRF2-mediated autophagy dysfunction and ferroptosis. Oxid. Med. Cell Longev. 2022, 2022, 9304383.
[43]	Badawy, A.M.; Taha, M.; Elazab, S.T.; El-Shenbaby, I.; Alghamdi, B.A.; Hendawy, M.; Al-Kushi, A.G.; Fathy, K.; Baokbah, T.A.S.; Ibrahim, M.M. Targeting of Nrf2/PPARγ/NLRP3 signaling pathway by stevia rebudiana bertoni extract provides a novel insight into its protective effect against acute gouty arthritis-induced synovial inflammation, oxidative stress and apoptosis in a rat model. Processes. 2022, 10, 1751.
[44]	Li, C.; Wang, C.; Guo, Y.J.; Wen, R.; Yan, L.P.; Zhang, F.R.; Gong, Q.F.; Yu, H. Research on the effect and underlying molecular mechanism of Cangzhu in the treatment of gouty arthritis. Eur. J. Pharmacol. 2022, 927, 175044.
[45]	Jia, P.; Chen, G.; Yang, J.; Qin, W.Y. Study on the effect of Simiao Pills on inflammation development and regulation of macrophage polarization in rats with gouty arthritis. Chin. J. TCM Pharm. 2022, 37, 3498–3502.
[46]	Shang, J.J.; Sun, C.; Wang, X.J.; Liu, H.Y. A retrospective study of spleen-activating and turbid pathogen-eliminating therapy in treatment of hyperuricemia with spleen deficiency. J. Anhui Univ. Chin. Med. 2021, 40, 38–42.
[47]	Zhang, S.Z.; Wang, Z.; Shi, X.L. Effect of invigorating spleen and turbidimetry on blood pressure. Hebei Med. 2012, 34, 771–772.
[48]	Xing, J.Y.; Meng, Y.; Li, Y.M.; Cui, J.L.; Wang, Y.J.; Gao, Y.B. Clinical observation of Jianpi Lishi Tongluo Decoction in treating type 2 diabetes mellitus with hyperuricemie. Beijing J. TCM. 2022, 41, 1110–1114.
[49]	Xie, X.C.; Gong, M.; Chen, W.W.; Yang, A.H.; Liu, M. Clinical observation of Lingbi Simiao Decoction combined with western medicine in the treatment of type 2 diabetes with hyperuricemia in spleen-kidney deficiency and turbid toxin internal resistance syndrome. Chin. J. TCM Pharm. 2021, 36, 5686–5688.
[50]	Chen, Y.; Fan, R.D.; Li, D. The clinical research on the therapeutic effect of metabolic syndrome with hyperuricemia by Yiqi huaju xiaoli fomula. CSTPCD. 2023, 24, 978–981, 985.